Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Dr Reddy's settles US...

    Dr Reddy's settles US probe for 5 million dollars

    Written by Ruby Khatun Khatun Published On 2017-12-19T11:44:32+05:30  |  Updated On 19 Dec 2017 11:44 AM IST
    Dr Reddys settles US probe for 5 million dollars

    Dr Reddy’s Laboratories Ltd will pay $5 million to resolve the U.S. claims that the Indian company sold prescription drugs in the United States in packaging that was not tested for child safety, according to court papers filed on Monday.


    The settlement was disclosed in documents filed in federal court in Trenton, New Jersey, over a year after the U.S. Consumer Product Safety Commission voted to refer a case involving the drugmaker to the U.S. Justice Department.


    Dr. Reddy’s in a statement said that the safety of patients and consumers was of “paramount importance” to the company. It said it disagreed with the allegations but agreed to the settlement to avoid prolonged litigation.


    “Dr Reddy’s is not aware of any reports that any child gained access to these products as a result of the packaging or that any of the products caused children harm as a result of the packaging,” the company said.


    The Justice Department alleged that in 2011, Dr Reddy’s engineers concluded the packaging for five types of drugs that the company manufactured and imported for sale would not pass tests required in the United States to prove child resistance


    The Justice Department in a lawsuit said that instead of notifying the CPSC or the public that its products put children at risk, the company quietly began altering its packaging while continuing to sell products in untested packaging.


    The lawsuit said Dr Reddy’s violated the Consumer Product Safety Act by distributing drugs that did not comply with a law aimed at protecting children from accidentally ingesting medicines by requiring those drugs to be in special packaging.


    Dr Reddy’s said products with the packaging at issue have not been distributed since June 2012.


    In addition to the $5 million penalties, Dr Reddy’s under the settlement must maintain a program aimed at ensuring compliance with consumer protection laws and must have a system to ensure information is reported to the CPSC.




    (Reporting by Nate Raymond in Boston; Editing by Leslie Adler)



    child safetyconsumer protection lawsDr ReddyDr Reddy'sDr Reddy's LaboratoriesDr Reddy's LabsDr. Reddy’s laboratories Ltddrug packagingdrug packaging casefederal courtlitigationpackagingpharma newsPrescription DrugssettlementsettlesUnited StatesUS Consumer Product Safety CommissionUS probe
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok